Alphatec falls after earnings miss and lowered guidance

What happened

Alphatec (ATEC) fell 38.1% on October 30, 2026, after reporting third-quarter results and cutting full-year revenue guidance because of weaker biologics and supply constraints. The company reported third-quarter 2026 results that showed revenue growth and improved profitability but missed at least one analyst EPS estimate. Management pointed to weaker biologics and add-on bone-graft sales, softer thoracolumbar procedure volumes and a temporary international supply bottleneck, according to Barron’s and Seeking Alpha. After the guidance cut and the sharp share-price decline, law firms Levi & Korsinsky and Ademi LLP said they were investigating possible securities fraud on behalf of investors who suffered losses, according to GlobeNewsWire and PRNewsWire.

How big was the move

The stock opened 39.7% below the previous close and closed at $7.04, with trading volume 9.8 times its 20-day average. The one-day change was a decline of 38.1% and the change over the last five sessions was a 36.6% fall. The move equated to 5.3 times a typical daily move for this stock, and it was company-driven because earnings were released at this session. By comparison, the S&P 500 fell 1.8% on the day and the Healthcare sector median fell 2.4%, leaving the stock 35.7 percentage points worse than the sector median.

The drop cut the company’s market value to $1.72 billion. Trading volume that was nearly 10 times its recent norm signalled a heavy exodus of positions. The stock’s market sensitivity, with a beta of 0.83, suggests it tends to move less than the broader market but has become highly volatile in the short term.

The technical picture

The stock is trading well below its short- and long-term averages: 33.8% below its 20-day moving average, 30.6% below its 50-day moving average and 33.3% below its 200-day moving average. The 50-day average is below the 200-day average, a sign of a weak longer-term trend. The Relative Strength Index (14 days) is 27, below 30, a level often called oversold.

Recent price action was steep. The stock fell 28.9% over one month and 30.6% over three months. Over one year the stock fell 57.3% and is 69.8% below the 52-week high. Volatility has surged to 113% annualized over 60 days, the highest reading of the past five years, underscoring rapid swings in sentiment and the potential for further short-term moves.

Fundamentals and valuation

For the four quarters through September 30, 2026, Alphatec reported revenue of $839.7 million, which grew 15.3% from a year earlier. Diluted earnings per share for the period were $-0.56, gross margin was 66.7% (a year earlier: 69.2%) and operating margin was 3.1% (a year earlier: 13.3%). Free-cash-flow margin was 0.6%, return on invested capital was 7.2%, and the balance sheet shows net debt of 15.9 times EBITDA. Share count over one year increased by 3.9%.

On valuation metrics the stock appears richly priced against its near-term cash generation: price to forward earnings is 21.6 times expected earnings and free-cash-flow yield is 0.3%. Those figures, together with a thin free-cash-flow margin and high net debt relative to EBITDA, help explain why investors reacted sharply to the guidance cut despite year-over-year revenue growth.

PromtFinance rankings paint a mixed picture: Value scored 68 (Positive), Growth 62 (Neutral) and Quality 60 (Neutral), while Momentum scored 9 (Very weak), Revisions 23 (Very weak) and Stability 26 (Very weak). The divergence between moderate fundamental scores and very weak momentum and revisions highlights investor concern about the near-term outlook.

Earnings and analyst expectations

The last report on October 29, 2026, showed earnings per share of $0.09 against $0.10 expected, 5.4% below estimates. Alphatec has zero consecutive quarters beating estimates and the average surprise over the last four reports is 100.0% below estimates. Historically the company’s typical two-day reaction after recent reports was a rise of 1.2%, a contrast with the current sharp decline.

Analysts maintain a consensus price target of $16.22, which is 130.4% above the closing price, based on 20 analysts and a consensus rating of Buy; 85% of those ratings are Buy or Strong Buy. The next report is scheduled for February 23, 2027. Given the miss and the guidance cut, investors will be watching whether analysts adjust estimates and price targets ahead of that date.

What to watch

• February 23, 2027: next scheduled earnings report
• Management commentary and any updates to the full-year revenue guidance
• Trends in biologics/add-on bone-graft product sales and thoracolumbar procedure volumes
• Any material developments in the announced securities fraud investigations
• Changes in trading volume relative to its 20-day average (currently 9.8 times)